|
Endo
Pharmaceuticals Holdings Inc
|
ENDP
Endo Pharmaceuticals Holdings
Inc., incorporated on November 18, 1997, is a specialty pharmaceutical
company specializing in pain management. The Company is engaged in the
research, development, sale and marketing of branded and generic prescription
pharmaceuticals used primarily to treat and manage pain
http://www.endo.com/
Endo
Pharmaceuticals Reports Strong Third Quarter Financial Results
18%
Growth in Net Sales Driven by Demand for Branded Products
Adjusted
EPS of $0.64 From Operations, Up 39% From 2007
Raises
2008 Adjusted EPS Guidance Range to $2.26 - $2.30
CHADDS
FORD, PA, Oct 30, 2008 (MARKET WIRE via COMTEX News Network) -- Endo Pharmaceuticals
(NASDAQ: ENDP) today reported double-digit growth in net sales and adjusted
earnings for the third quarter of 2008.
Net
sales during the third quarter of 2008 increased 18% to $316.8 million
compared with $269.5 million in the third quarter of 2007. Net income for
the three months ended September 30, 2008 was $68.2 million compared with
$59.1 million in the comparable 2007 period. As detailed in the Supplemental
Financial Information below, adjusted net income for the three months ended
September 30, 2008 was $76.1 million compared with $61.6 million in the
same period in 2007.
Diluted
earnings per share for the three months ended September 30, 2008 were $0.57
compared with $0.44 in the third quarter of 2007. Adjusted diluted earnings
per share for the three months ended September 30, 2008 were $0.64 compared
with $0.46 in the same period in 2007.
Net
sales for the nine months ended September 30, 2008 were $913.2 million
compared with $781.0 million in the comparable 2007 period. Diluted earnings
per share for the nine months ended September 30, 2008 were $1.48 compared
with $1.31 in the comparable 2007 period. Adjusted diluted earnings per
share for the nine months ended September 30, 2008 were $1.70 compared
with $1.40 in the same period in 2007.
Selected
Product Review
LIDODERM(R):
For the quarter ended September 30, 2008, net sales of LIDODERM increased
11% to $194.1 million compared with $174.3 million in the same period a
year ago. Prescription volume for LIDODERM increased 7% in the third quarter
of 2008 versus the comparable 2007 period. For the nine months ended September
30, 2008, net sales of LIDODERM increased 13% to $559.7 million compared
with $496.9 million in the same period a year ago. Prescription volume
for LIDODERM increased 8% in the nine months of 2008 versus the comparable
2007 period.
OPANA(R)
ER and OPANA(R): Combined net sales for the OPANA franchise increased 73%
to $41.5 million for the third quarter 2008 compared with $24.0 million
in the same period a year ago. Prescription volume for OPANA ER and OPANA
increased 80% in the third quarter 2008 versus the comparable 2007 period.
For the nine months ended September 30, 2008, net sales for the OPANA franchise
increased 64% to $128.2 million compared with $78.3 million in the same
period a year ago. The 2007 nine month results include the recognition
of $13.8 million in deferred revenue for commercial shipments of OPANA
ER and OPANA made to customers in 2006.
PERCOCET(R):
Net sales of PERCOCET were $31.4 million for the three months ended September
30, 2008 compared with $31.6 million in the same period in 2007. Net sales
of PERCOCET were $96.6 million for the nine months ended September 30,
2008 compared with $91.2 million in the same period in 2007.
FROVA(R):
Net sales of FROVA were $14.3 million for the three months ended September
30, 2008 compared with $13.5 million for the same period in 2007. Prescription
volume increased 11% for the first nine months of 2008 versus the comparable
2007 period. For the nine months ended September 30, 2008, net sales of
FROVA were $41.2 million compared with $38.4 million in the same period
in 2007.
VOLTAREN(R)
GEL: Net sales of VOLTAREN GEL were $11.3 million for the nine months ended
September 30, 2008.
Generic
Products: For the third quarter of 2008, net sales from the company's generic
products were $22.4 million compared with $23.3 million in the same period
in 2007. For the nine months ended September 30, 2008, net sales of the
company's generic products were $68.2 million compared with $68.4 million
in the same period in 2007.
Share
Repurchase Program: Under the company's authorized share repurchase program
approved in April 2008 by Endo's board of directors, the company has repurchased
17.7 million shares.
2008
Financial Guidance
Endo
Pharmaceuticals raises its adjusted full-year 2008 earnings guidance range
for fully diluted earnings per share from $2.15-$2.19 to $2.26-$2.30. The
company reiterates guidance for 2008 annual net sales to be between $1.245
billion and $1.280 billion. The financial guidance for 2008 excludes the
impact of any future business development transactions or acquisitions,
estimated milestone payments to partners, certain contract termination
costs, the expensing of stock-based compensation charges, certain separation
benefits, and any asset impairment charges.
Endo
Pharmaceuticals Reports First Quarter Financial Results
Company
Raises 2008 Guidance
CHADDS
FORD, PA, Apr 30, 2008 (MARKET WIRE via COMTEX News Network) -- Endo Pharmaceuticals
Holdings Inc. (NASDAQ: ENDP), a specialty pharmaceutical company with market
leadership in pain management, today reported financial results for the
three months ended March 31, 2008.
Net
sales in the first quarter of 2008 were $290.3 million compared with $254.4
million in the first quarter of 2007, a 14.1% increase. Net income for
the three months ended March 31, 2008 was $59.5 million compared with $57.1
million in the comparable 2007 period. As detailed in the Supplemental
Financial Information below, adjusted net income for the three months ended
March 31, 2008 was $68.3 million compared with $62.5 million in the same
period in 2007.
Diluted
earnings per share for the three months ended March 31, 2008 were $0.44
compared with $0.43 in the first quarter of 2007. As detailed in the Supplemental
Financial Information below, adjusted diluted earnings per share for the
three months ended March 31, 2008 were $0.51 compared with $0.47 in the
same period in 2007.
"The
financial results achieved in the quarter reflect Endo's strong financial
condition and solid foundation for the future," said Charles A. Rowland,
Jr., Chief Financial Officer. "To make optimal use of our strong balance
sheet, we recently announced a $750 million share repurchase program, and
in connection therewith, successfully completed a private offering of $379.5
million of convertible senior subordinated notes and a $325 million accelerated
share repurchase agreement. These actions reflect the confidence of the
Board and management in Endo's future prospects and strong cash flow."
Endo
Pharmaceuticals to Hold Conference Call on Fourth Quarter and Full-Year
2007 Financial Results
CHADDS
FORD, PA, Feb 18, 2008 (MARKET WIRE via COMTEX News Network) -- Endo Pharmaceuticals
Holdings Inc. (NASDAQ: ENDP), a market leader in pain management, will
announce its financial results for the fourth quarter and full-year ended
December 31, 2007 before the market opens on February 22, 2008, and will
hold a conference call at 11:00 a.m. ET that day to discuss these results.
Nancy
J. Wysenski, Chief Operating Officer, Charles A. Rowland, Jr., Chief Financial
Officer, and David A. Lee, M.D., Ph.D., Chief Scientific Officer, will
host the call.
Investors
and other interested parties may access the conference call as follows:
Telephone
Numbers
888-713-4205
(domestic), (617) 213-4862 (international)
Passcode:
37096907
Please
dial in 10 minutes prior to the scheduled start time.
Replay
A
replay of the call will be available from February 22, 2008 at 1:00 p.m.
ET by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international),
passcode 90683726, and will run until 12:00 a.m. ET on February 29, 2008.
Webcast
A
simultaneous webcast of the call for interested investors and others may
be accessed by visiting www.endo.com. In addition, a replay of the webcast
will be available until 12:00 a.m. ET on February 29, 2008. The replay
can be accessed by clicking on "Events" in the Investor Relations section
of the website.
|
